LUCD (Lucid Diagnostics) Change In Receivables: $-0.63 Mil (TTM As of Mar. 2026)


LUCD Lucid Diagnostics Inc LUCD
20 GF Score
Price $1.00
GF Value $0.82
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics Change In Receivables?

Lucid Diagnostics LUCD +2.03% 20 Change In Receivables is $-0.63 Mil as of Mar. 2026. GuruFocus rates LUCD with a GF Score™ of 20/100 and a GF Value™ of $0.82 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Lucid Diagnostics's change in receivables for the quarter that ended in Mar. 2026 was $-0.05 Mil. It means Lucid Diagnostics's Accounts Receivable increased by $0.05 Mil from Dec. 2025 to Mar. 2026 .

Lucid Diagnostics's change in receivables for the fiscal year that ended in Dec. 2025 was $-0.60 Mil. It means Lucid Diagnostics's Accounts Receivable increased by $0.60 Mil from Dec. 2024 to Dec. 2025 .

Lucid Diagnostics's Accounts Receivable for the quarter that ended in Mar. 2026 was $0.69 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Lucid Diagnostics's Days Sales Outstanding for the three months ended in Mar. 2026 was 50.06.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Lucid Diagnostics's liquidation value for the three months ended in Mar. 2026 was $-1.45 Mil.

Lucid Diagnostics  (NAS:LUCD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Lucid Diagnostics's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.689/1.256*91
=50.06

2. In Ben Graham's calculation of liquidation value, Lucid Diagnostics's accounts receivable are only considered to be worth 75% of book value:

Lucid Diagnostics's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=27.876-30.08+0.75 * 0.689+0.5 * 0.469
=-1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucid Diagnostics Change In Receivables Related Terms

Lucid Diagnostics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Lucid Diagnostics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucid Diagnostics Change In Receivables Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial -0.20 0.18 -0.03 0.00 -0.60

Lucid Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.31 -0.18 -0.10 -0.05
LUCD
20GF Score
Lucid Diagnostics Inc LUCD
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lucid Diagnostics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.63 Mil mean?
Lucid Diagnostics (LUCD) has a Change In Receivables of $-0.63 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Lucid Diagnostics and its competitors.
Is Lucid Diagnostics' Change In Receivables too high?
Lucid Diagnostics' current Change In Receivables is $-0.63 Mil. Overall, Lucid Diagnostics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Change In Receivables compare to QTRX and INFU?
Lucid Diagnostics' Change In Receivables of $-0.63 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Lucid Diagnostics and its competitors. Lucid Diagnostics's current Change In Receivables is $-0.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.82, compared to a current price of $1.00 — trading 22% above its estimated fair value. The current Change In Receivables is $-0.63 Mil. Lucid Diagnostics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Change In Receivables is $-0.63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $1.00 is trading 22% above its estimated GF Value™ of $0.82. GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.

Key valuation signals for LUCD:

  • Change In Receivables: $-0.63 Mil
  • GF Value™: $0.82 vs. price of $1.00 (22% above fair value)
  • GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
20GF Score

Get the complete analysis for LUCD

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price
$0.82
GF Value